Description

Alcon’s $550 Million Acquisition Could Transform Its Retinal Business—Here’s How!

Alcon has expanded its ophthalmology portfolio with the acquisition of privately held Neurotech Pharmaceuticals for $550 million, alongside potential additional payments tied to commercial milestones. Announced on October 20, 2026, the transaction gives Alcon ownership of ENCELTO (revakinagene taroretcel-lwey), the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare retinal disease that progressively damages central vision. Approved in March 2025, ENCELTO introduces an encapsulated cell therapy platform into Alcon’s established surgical retina business. The acquisition follows a strong second quarter in which Alcon delivered 7% sales growth to approximately $2.8 billion, supported by its UNITY surgical platform, premium intraocular lenses, and ocular health products. With approximately 25,000 diagnosed MacTel patients in the United States, the transaction presents an opportunity to expand Alcon’s retinal treatment capabilities, leverage existing surgeon relationships, and develop a differentiated position in sustained-release ophthalmic therapeutics.